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 1), which is possible, then there is at most 5%









icantly) and to recommend the truly inferior treatment cou-
marin that in addition has the more burdensome regimen.
 




suppose that coumarin is really inferior
 
 to aspi-








 1. The two-sided significance level 0.05
implies a 2.5% chance to recommend the truly inferior treat-








 1 significantly. The one-
sided significance level 0.05 implies a 5% chance to recom-
mend the truly inferior treatment coumarin, and this greater
chance to recommend a truly inferior treatment was chosen
because of the added disadvantage of a more burdensome
regimen. In my opinion, the chance to recommend a truly
inferior treatment with a more burdensome regimen should
be less than (or equal to) the chance to recommend a truly
inferior treatment without a burdensome regimen, contrary
to the advice by Knottnerus and Bouter [1]. A larger signifi-
cance level may be chosen in an equivalence trial where the
reference intervention is more burdensome. The next para-




Section 5.5 of an international (European Union, Japan,
United States) guideline [3], on statistical principles for clinical
trials, prefers the approach of setting the significance level for
one-sided tests at half the conventional significance level for
two-sided tests, because “this promotes consistency with the
two-sided confidence intervals that are generally appropriate
for estimating the possible size of the difference between two





vince [4] your colleagues if the 95% confidence interval for the








In an interim analysis an O’Brien-Fleming 95% confi-
dence interval for the true relative risk may be computed. The









 1 and thus indicates statistical significance [5].















 1.80, excludes a relative risk that is clinically
relevant. Notice that this example interval, from 0.92 to 1.80,
would stop the trial only in case a one-sided test was chosen,
not in case a two-sided test was chosen.
 
5. Unequal sample sizes
 
It is more efficient to have about the same number of events
in each treatment group, instead of the same number of patients
[6,7]. Suppose that investigators demand 90% power to detect
the relative risk RRtrue  2/3. If naspirin  (2/3)ncoumarin is cho-
sen, then 1,833 patients should enter the study, 733 on aspirin
and 1,100 on coumarin, and 220 events are expected in 1833 
2.5 patient years. In case of equal group sizes, 1840 patients
should enter the study and 230 events are expected. Warning:
in case unequal sample sizes are planned for a survival analy-
sis, wrong answers are obtained from a sample size formula for
comparing proportions in a Pearson chi-squared test.
6. Conclusion
Knottnerus and Bouter [1] rightly explained that a one-
sided test may be preferred in certain cases, but they should
pay attention to the chance to recommend a truly inferior
treatment. The significance level for a one-sided test should
be half the appropriately chosen significance level for a
two-sided test. In case interim analyses are planned, a one-
sided view may stop a trial earlier than a two-sided view.
Hubert J. A. Schouten
Department of Methodology and Statistics,
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The ethics of sample size: The whole picture should be 
considered
At variance with Schouten’s interpretation, we aim to opti-
mize, rather than “minimize” study size, to expose enough but
not too many subjects to an experimental regimen to answer
the key question at stake [1–3]. The first and foremost concern
is to specify that question, with the preferred statistical ap-
proach being the consequence of it. As we formulated earlier
[1]: a research hypothesis is no “random shooting” but ex-
presses scientific uncertainty regarding a plausible, potentially
clinically important effect. Before a trial one is not totally igno-
rant of what is to be tested. The problem at issue is generally
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not as neutral as: “is the principal treatment better than the ref-
erence (A  B), or does it equal the reference (A  B), or is it
worse than the reference (A  B)?” Often, the question is
“whether the principal treatment is indeed better than the refer-
ence,” considering that an advantage of the principal over the
reference intervention is a reasonable but not sufficiently tested
assumption. A proper research question is in many cases “one-
sided” [4]. A further consideration is: what are the conse-
quences of the possible outcomes (A  B, A  B, or A  B) in
terms of study conclusions and recommendations for practice.
In many instances there is no reason to distinguish between
equivalence and inferiority of the more burdensome interven-
tion. We maintain our view that one-sided testing and a corre-
sponding sample size estimation is the preferred approach if (a)
the scientific hypothesis to be tested is obviously one-sided, or
if (b) only a clear advantage in effect of the principal over the
reference intervention would have consequences for practice.
Starting from the principle of one-sided testing while main-
taining the same power, this will imply a smaller study size than
if two-sided testing is chosen, unless—as Schouten advocates—
in the one-sided option half the significance level as used in the
two-sided approach would be applied. Of course, a more strin-
gent significance level will decrease the probability of a false sig-
nificant result if the principle intervention is actually equivalent
or inferior. Where to draw the line is a matter of judgement,
rather than being evident and unequivocal. Why not use a one-
sided significance level of 0.025 or even more strict, 0.01 or
0.001, instead of 0.05? This depends on the research topic, clini-
cal implications, the acceptable amount of uncertainty, and ethi-
cal considerations, and has substantial consequences for the study
budget. But this choice is fully independent of the essential differ-
ence between one- and two-sided testing. In the first option, there
is one clear alternative for the null hypothesis (A  B). In the sec-
ond, there are in fact two alternative hypotheses (A  B and A 
B). Accordingly, we do not agree with Schouten’s implicit sug-
gestion that for both situations the same sample size should be
used. Instead, testing two alternative hypotheses requires more
evidence, that is, a larger sample size than testing one.
A further comment on Schouten’s analysis is that, in line
with the frequentists’ view on hypothesis testing, he ignores
the prior probability of the alternative hypothesis (e.g., A 
B) being true given prior scientific work and reasoning. We
favor the Bayesian approach, and believe that the posterior
probability (after the study being done), that an observed
statistically significant effect of A is, in fact, falsely signifi-
cant, is lower as the prior probability of A being actually
better is higher. Also, the higher the prior probability of the
alternative hypothesis A  B being true, the more a one-
sided hypothesis will be justified and preferable. In testing a
well-prepared one-sided hypothesis with a one-sided signif-
icance level set at 0.05, the posterior probability of a false
significant effect may, therefore, be even lower than in test-
ing a “scientifically neutral” hypothesis at the .025 level.
Schouten prefers setting the significance level for one-sided
tests at half the “conventional” significance level for two-sided
tests, also “because this promotes consistency with the two-
sided confidence intervals that are generally appropriate for es-
timating the possible size of the difference between two treat-
ments,” and states that an interval including RR  1.0 would
not be convincing to colleagues. In response, we emphasize
that the 95% confidence interval is not a fixed thing, nor a nat-
ural phenomenon. In case of a one-sided hypothesis, one is in-
terested in whether the interval limit directed towards the null
value (RR  1.0) would include 1.0 or not. For that purpose, in
case of a significance level of 0.05, a one-sided 90% limit
would suffice. Those who think that this is too unconventional
of difficult to interpret may choose not to use confidence inter-
vals in cases like this. Significance testing would be sufficient,
because the fundamental issue in the discussed example is not
a matter of estimation and quantification but of hypothesis test-
ing. That is, deciding on whether the principal treatment to be
tested is indeed better that the reference or not.
The fact that in case of a one-sided focus (hypothesis) a
trial might be stopped earlier (that is, being conclusive in an
earlier stage) compared with the two-sided approach is sim-
ply a consequence of the fundamental difference between
both approaches. In fact, in the “one-sided situations” out-
lined in our earlier contributions, an earlier stop would be not
only justified but even highly desirable. As we earlier have
stipulated [2], the possibility to apply stopping rules is not the
monopoly of the two-sided approach. Such rules can also be
implemented according to a one-sided approach, both regard-
ing primary end points and adverse effects [5–7].
Finally, in speaking about superior or inferior treatments,
one must distinguish between studies focussing on primary
clinical endpoints (which may include intentionally evalu-
ated adverse effects, e.g., when looking at the incidence of
both stroke and bleeding in a warfarin trial) and studies es-
pecially designed to detect or exclude infrequent and typi-
cally unsuspected adverse effects. The latter type of studies
have specific requirements, regarding both methodology
and sample size estimation [8].
J. André Knottnerus, Lex M. Bouter
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